Abstracts tagged "mesenchymal stem cells and rheumatoid arthritis"

Abstract Number: 39 • 2018 ACR/ARHP Annual Meeting
Allogeneic Mesenchymal Stem Cells Derived Extracellular Vesicles As a Superior Immunosuppressant in Murine Arthritis Therapy
Runci Wang^1,2, Yi Liu^3,4 and Songtao Shi⁵, ¹Department of Anatomy and cell biology, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA, ²Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, China, ³Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, Sichuan, China, Chengdu, China, ⁴Department of Rheumatology and Immunology, West China Hospital of Sichuan University, Chengdu, China, ⁵Department of Anatomy and Cell Biology, School of Dental Medicine, University of Pennsylvania,, Philadelphia, PA
Allogeneic mesenchymal stem cells derived extracellular vesicles as a superior immunosuppressant in murine arthritis therapyRunci Wang1,2, Yi Liu2, Songtao Shi1Affiliation: 1. Department of Anatomy and…
Abstract Number: 2557 • 2015 ACR/ARHP Annual Meeting
Comparable Therapeutic Potential of Umbilical Cord Mesenchymal Stem Cells in Collagen Induced Arthritis with Anti-Tumor Necrosis Factor or Anti-CD20
Yue Sun, Wei Kong, Weiwei Chen, Genhong Yao, Xuebing Feng and Lingyun Sun, Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China
Background/Purpose: Tremendous progress has been made in the development of non-conventional therapies for rheumatoid arthritis (RA). Mesenchymal stem cells (MSC) present multiple immunosuppressive capacities and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].